The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling
Open accessAbstract
Inflammation in arterial walls leads to coronary artery disease (CAD). Because specialized proresolving lipid mediators (SPMs; lipoxins, resolvins, and protectins) stimulate resolution of inflammation in animal models, we tested whether n‐3 fatty acids impact SPM profiles in patients with CAD and promote clot remodeling. Six patients with stable CAD were randomly assigned to either treatment with daily 3.36 g Lovaza for 1 yr or without. Targeted lipid mediator‐metabololipidomics showed that both groups had absence of resolvin D1 (RvD1), RvD2, RvD3, RvD5 and resolvin E1—all of which are present in healthy patients. Those not taking Lovaza had an absence of aspirin‐triggered resolvin D3 (AT‐RvD3) and aspirin‐triggered lipoxin B 4 (AT‐LXB 4 ). Lovaza treatment restored AT‐RvD3 and AT‐LXB 4 and gave levels of RvD6 and aspirin‐triggered protectin D1 (AT‐PD1) twice as high (resolvin E2 ~5 fold) as well as lower prostaglandins. Principal component analysis indicated positive relationships for patients with CAD who were receiving Lovaza with increased AT‐RvD3, RvD6, AT‐PD1, and AT‐LXB4.SPMs identified in Lovaza‐treated patients with CAD enhanced ~50% at 1 nM macrophage uptake of blood clots. These results indicate that patients with CAD have lower levels and/or absence of specific SPMs that were restored with Lovaza; these SPMs promote macrophage phagocytosis of blood clots. Together, they suggest that low vascular SPMs may enable progression of chronic vascular inflammation predisposing to coronary atherosclerosis and to thrombosis.—Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., Welty, F. K. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 30, 2792‐2801 (2016). www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“aspirin-triggered, pro-resolving omega-3 fatty acid derivatives can be detected in patients with diabetes and coronary artery disease who were treated with a mixture of DHA and EPA concomitantly with aspirin and statins126.”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Self-citationn−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525
(1999) · PubMed · Cited by 2,062
Psychogios, N., Hau, D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinelnikov, I. V., Krishnamurthy, R., Eisner, R., Gautam, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016957 · Cited by 1,779
Robbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2005) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000155072.86944.7d · Cited by 1,566
Lipid mediator class switching during acute inflammation: signals in resolution
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001) · Nature Immunology · doi:10.1038/89759 · Cited by 1,453
Self-citationDistribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Cited by
Sorted by citations
Items 101–144 of 144
Wang, Y., Zhu, X.-T., & Hu, Z.-P. (2025) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2025.106990 · Cited by 8
Inflammation-resolution signalling in cardiac repair, remodelling, and heart failure
Halade, G. V., Bäck, M., & Kain, V. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf157 · Cited by 9
Specialized pro-resolving receptors are expressed in salivary glands with Sjögren's syndrome
dos Santos, H. T., Nam, K., Maslow, F., Trump, B., & Baker, O. J. (2021) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2021.151865 · Cited by 9
Ibi, A., Chang, C., Kuo, Y. C., Zhang, Y., Du, M., Roh, Y. S., Gahler, R. J., Hardy, M. L., & Solnier, J. (2024) · Metabolites · doi:10.3390/metabo14050265 · Cited by 9
Amedei, A., Lamminpää, I., & Parolini, C. (2025) · Biomedicines · doi:10.3390/biomedicines13102428 · Cited by 6
dos Santos, H. T., Nam, K., Gil, D., Yellepeddi, V., & Baker, O. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1094278 · Cited by 6
Chen, R., Li, J., Sheng, Z., Zhou, J., Wang, Y., Zhao, X., Li, N., Liu, W., Liu, C., Zhou, P., et al. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s433404 · Cited by 6
Sun, X., Feng, Y., Zhao, Y., Cai, Y., Cao, Z., Zhang, Y., Wei, Z., Du, A., & Xu, B. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag017 · Cited by 6
Fine-tuning inflammation-resolution programs
Fredman, G., Sadhu, S., & Rymut, N. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000351 · Cited by 4
Wang, I. E., Yi, S., Block, R., & Mousa, S. A. (2021) · Nutrition Research Reviews · doi:10.1017/s0954422421000238 · Cited by 4
Korpak, K., Rossi, M., MEERHAEGHE, A. V., Boudjeltia, K. Z., & Compagnie, M. (2024) · Nutrition and Healthy Aging · doi:10.3233/nha-220184 · Cited by 4
Platelet inhibition by low-dose aspirin is not influenced by body mass or weight
Heffron, S. P., Windheim, J., Barrett, T. J., Voora, D., & Berger, J. S. (2022) · Platelets · doi:10.1080/09537104.2022.2087868 · Cited by 3
dos Santos, H. T., Maslow, F., Nam, K., Trump, B., Weisman, G. A., & Baker, O. J. (2022) · JADA Foundational Science · doi:10.1016/j.jfscie.2022.100016 · Cited by 3
Biologically Active Lipids in Vascular Biology
Upchurch, C. M., & Leitinger, N. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-12270-6_9 · Cited by 3
Dietary Modulation of Chronic Inflammation of Diabetes: A Narrative Review
Joseph, S. (2023) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000181 · Cited by 2
Gonçalves, W. A., Melão, A. C. R., Teixeira, M. M., Rezende, B. M., & Pinho, V. (2018) · Springer eBooks · doi:10.1007/978-3-319-77658-3_6 · Cited by 3
Resolvin the clot: DVT resolution through RvD4
Holinstat, M. A. (2019) · Blood · doi:10.1182/blood.2019002419 · Cited by 3
Brianza-Padilla, M., & Bojalil, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-21735-8_5 · Cited by 2
Regidor, P., Eiblwieser, J., Steeb, T., & Rizo, J. M. (2024) · F1000Research · doi:10.12688/f1000research.153569.3 · Cited by 2
Anti-inflammatory and Atheroprotective Properties of Omega-3 Polyunsaturated Fatty Acids
Sorokin, A. V., Yang, Z. H., & Remaley, A. T. (2016) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000478 · Cited by 2
Effect of Omega3 for the Skin Diseases- A Review
Alyassery, A. M. A., Al-Jammali, Z. M., & Al-Yasiry, A. M. (2023) · Journal of University of Babylon for Pure and Applied Sciences · doi:10.29196/jubpas.v31i3.4822 · Cited by 1
McGowan, N. G., Zhong, J. H., Trasande, L., Hellmann, J. L., & Heffron, S. P. (2024) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20240043 · Cited by 1
Macrophage Plasticity and Immune Remodeling in Ischemic Heart Failure
Xiao, C., MacDonald, L., Epelman, S., & Lavine, K. J. (2026) · Immunological Reviews · doi:10.1111/imr.70137 · Cited by 1
Resolvins: The resolving mediators divulged
Muralidharan, R., Basavaraju, S., & Vidya Priyadharshini, D. S. (2023) · International Journal of Applied Dental Sciences · doi:10.22271/oral.2023.v9.i1b.1659 · Cited by 1
Regidor, P., Eiblwieser, J., Steeb, T., & Rizo, J. M. (2024) · F1000Research · doi:10.12688/f1000research.153569.1 · Cited by 1
Markers of oxidative stress after three days of nanoTiO2 sunscreen use in humans: a pilot study
Pelclová, D., Navrátil, T., Fenclová, Z., & Vlčková, Š. (2020) · Central European Journal of Public Health · doi:10.21101/cejph.a6158 · Cited by 1
Fatty Acids and Immunomodulation
Shahrul, H., & Tasyriq, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-6379-6_15 · Cited by 1
del Villar, R. S., Ortega-Hernandez, J. A., Pérez, L. F., Sánchez‐Muñoz, F., Martínez, J. C. A., González‐Pacheco, H., & Bojalil, R. (2018) · Gaceta Médica de México · doi:10.24875/gmm.18004572
Next-Gen Inflammation Resolution
Fredman, G. (2020) · Circulation Research · doi:10.1161/circresaha.119.316248
Insulin resistance and heart disease
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819603-8.00003-1
Keeley, E. C., Handberg, E. M., Wei, J., Merz, C. N. B., & Pepine, C. J. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100098
Xu, H., Xu, S., Li, L., Wu, Y., Mai, S.-Y., Xie, Y., Tan, Y., Li, A., Xue, F., He, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21629187
Biologically Active Lipids in Vascular Biology
Upchurch, C. M., & Leitinger, N. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_9
Impacts of Oxylipins on ischemic stroke: from pathophysiology to clinical phenotypes
Cheng, L., & Xia, J. (2025) · Metabolomics · doi:10.1007/s11306-025-02324-1 · Cited by 1
Xu, H., Xu, S., Li, L., Wu, Y., Mai, S., Xie, Y., Tan, Y., Li, A., Xue, F., He, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21629184
Xu, H., Xu, S., Li, L., Wu, Y., Mai, S., Xie, Y., Tan, Y., Li, A., Xue, F., He, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21629181
Xu, H., Xu, S., Li, L., Wu, Y., Mai, S., Xie, Y., Tan, Y., Li, A., Xue, F., He, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21629190
Xu, H., Xu, S., Li, L., Wu, Y., Mai, S., Xie, Y., Tan, Y., Li, A., Xue, F., He, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21629178
Jiang, Y., & Du, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1728794
Bouhadoun, A. (2022) · theses.fr (ABES) · doi:10.70675/774cb3d0z938ez4b96z85ffze9119702485e
Wang, S., Lu, W., Ge, L., Wu, H., Wu, J., Cheng, K., Xiao, H., Wang, X., Huang, F., Wang, S., et al. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2649917
Snodgrass, R. G., Stephensen, C. B., Armstrong, P., Allayee, H., Snodgrass, I. F., Laugero, K. D., & Newman, J. W. (2026) · Mediators of Inflammation · doi:10.1155/mi/8899139
Lotfi, R., Nasirifar, A., Rahmani, H., Falahi, S., & Kashiri, M. (2026) · Health Science Reports · doi:10.1002/hsr2.73012
Subramanian, M. (2026) · Current topics in microbiology and immunology · doi:10.1007/82_2026_361
Metadata
- Authors
- Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., & Welty, F. K.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Welty, Francine K.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2016-04-27
- Volume
- 30
- Issue
- 8
- Pages
- 2792-2801
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC4970606
- OpenAlex
- W2344216384
- Cited by
- 143
- References
- 51
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 11 · 2023: 17 · 2022: 23 · 2021: 10 · 2020: 15 · 2019: 19 · 2018: 13 · 2017: 17 · 2016: 5
- FWCI
- 18.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (P01GM095467, RO1GM03865, P50HL083813)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- coronary artery disease, omega-3 fatty acids, lipoxin B4, protectin D1, vascular inflammation, thrombosis, atherosclerosis
- MeSH terms
- Aged, Aspirin, Coronary Disease, Docosahexaenoic Acids, Drug Combinations, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Eicosapentaenoic Acid, Biomarkers, Fatty Acids, Omega-3, Lipoxins, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
